HUMAN STEM CELLS INSTITUTE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.54 RUB | +1.43% |
|
-.--% | -.--% |
| Sales 2021 | 1.18B 12.63M | Sales 2022 | 1.14B 12.16M | Capitalization | 4.29B 45.84M |
|---|---|---|---|---|---|
| Net income 2021 | 11M 118K | Net income 2022 | 46M 492K | EV / Sales 2021 | 7.36 x |
| Net Debt 2021 | 423M 4.53M | Net Debt 2022 | 605M 6.47M | EV / Sales 2022 | 4.3 x |
| P/E ratio 2021 |
790
x | P/E ratio 2022 |
112
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
1.68% | Free-Float | 22.77% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.43% |
3 years
34.34
177.00
5 years
8.08177.00
10 years
7.60177.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 54 | 03-11-26 | |
| Director of Finance/CFO | - | - | |
| Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrey Isaev
BRD | Director/Board Member | 53 | 07-06-27 |
| Director/Board Member | 65 | 04-01-04 | |
Sergey Kiselev
BRD | Director/Board Member | 66 | 07-06-27 |
Institut Stvolovykh Kletok Cheloveka PAO (Human Stem Cells Institute OJSC or HSCI OJSC) is a Russia-based company engaged in the research and development, as well as commercialization and marketing of proprietary products and services in the areas of cell-based and gene and post-genome technologies. The Company is engaged in such projects as: Gemabank, cord blood stem cells bank; Gemascreen medical genetic diagnostics and consulting services provided by the Company domestically with the aim of early detection, treatment or prevention of inherited diseases; SPRS-therapy service a set of personalized diagnostics and treatment procedures; SynBio, which focuses on development of new medicines. In addition, the Company is a producer of Neovasculgen, a gene-therapy drug. In February 2014, it opened a biotech complex in Kyiv.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 47.29M | |
| -12.23% | 86.52B | |
| +19.64% | 85.39B | |
| +12.75% | 29.95B | |
| -9.59% | 17.31B | |
| -9.33% | 15.23B | |
| -6.46% | 14.27B | |
| +2.75% | 12.23B | |
| -29.82% | 11.68B | |
| +25.08% | 11.44B |
- Stock Market
- Equities
- ISKJ Stock
